Designer Drugs for Designer Receptors: Unlocking the Translational Potential of Chemogenetics

Ofer Yizhar; J. Simon Wiegert

doi:10.1016/j.tips.2019.04.010

Designer Drugs for Designer Receptors: Unlocking the Translational Potential of Chemogenetics

Ofer Yizhar, J. Simon Wiegert

Weizmann Institute of Science

Weizmann Institute of Science

Research output: Contribution to journal › Article › peer-review

Abstract

Chemogenetic techniques allow selective manipulation of neurons by activating engineered actuator proteins with otherwise inert effector molecules. A recent study (Magnus et al. Science 2019;364: eaav5282) describes the coevolution of highly potent actuator effector pairs based on a clinically approved antismoking drug. These tools allow selective excitation or inhibition of neurons in the living brain with high specificity and no detectable side-effects.

Original language	English
Pages (from-to)	362-364
Number of pages	3
Journal	Trends in Pharmacological Sciences
Volume	40
Issue number	6
Early online date	6 May 2019
DOIs	https://doi.org/10.1016/j.tips.2019.04.010
State	Published - Jun 2019

Access to Document

10.1016/j.tips.2019.04.010

https://europepmc.org/article/PMC/6548557License: Unspecified

Cite this

@article{cd02391f817b4a7db4b15e114011d97a,

title = "Designer Drugs for Designer Receptors: Unlocking the Translational Potential of Chemogenetics",

abstract = "Chemogenetic techniques allow selective manipulation of neurons by activating engineered actuator proteins with otherwise inert effector molecules. A recent study (Magnus et al. Science 2019;364: eaav5282) describes the coevolution of highly potent actuator effector pairs based on a clinically approved antismoking drug. These tools allow selective excitation or inhibition of neurons in the living brain with high specificity and no detectable side-effects.",

author = "Ofer Yizhar and Wiegert, {J. Simon}",

note = "We thank Mauro Pulin for comments on this manuscript. This work was supported by grants from the Adelis Foundation (to O.Y.), the European Research Council (ERC-2016-StG 714762 to J.S.W., ERC-2018-CoG 819496 to O.Y.) and the Deutsche Forschungsgemeinschaft (DFG FOR 2419, DFG SPP 1926 to J.S.W.).",

year = "2019",

month = jun,

doi = "10.1016/j.tips.2019.04.010",

language = "الإنجليزيّة",

volume = "40",

pages = "362--364",

journal = "Trends in Pharmacological Sciences",

issn = "0165-6147",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - Designer Drugs for Designer Receptors: Unlocking the Translational Potential of Chemogenetics

AU - Yizhar, Ofer

AU - Wiegert, J. Simon

N1 - We thank Mauro Pulin for comments on this manuscript. This work was supported by grants from the Adelis Foundation (to O.Y.), the European Research Council (ERC-2016-StG 714762 to J.S.W., ERC-2018-CoG 819496 to O.Y.) and the Deutsche Forschungsgemeinschaft (DFG FOR 2419, DFG SPP 1926 to J.S.W.).

PY - 2019/6

Y1 - 2019/6

N2 - Chemogenetic techniques allow selective manipulation of neurons by activating engineered actuator proteins with otherwise inert effector molecules. A recent study (Magnus et al. Science 2019;364: eaav5282) describes the coevolution of highly potent actuator effector pairs based on a clinically approved antismoking drug. These tools allow selective excitation or inhibition of neurons in the living brain with high specificity and no detectable side-effects.

AB - Chemogenetic techniques allow selective manipulation of neurons by activating engineered actuator proteins with otherwise inert effector molecules. A recent study (Magnus et al. Science 2019;364: eaav5282) describes the coevolution of highly potent actuator effector pairs based on a clinically approved antismoking drug. These tools allow selective excitation or inhibition of neurons in the living brain with high specificity and no detectable side-effects.

U2 - 10.1016/j.tips.2019.04.010

DO - 10.1016/j.tips.2019.04.010

M3 - مقالة

C2 - 31072638

SN - 0165-6147

VL - 40

SP - 362

EP - 364

JO - Trends in Pharmacological Sciences

JF - Trends in Pharmacological Sciences

IS - 6

ER -

Designer Drugs for Designer Receptors: Unlocking the Translational Potential of Chemogenetics

Abstract

Access to Document

Fingerprint

Cite this